AgelessRx has released a prescription copper peptide (GHK-Cu) cream in two compounded strengths, 0.5% and 3%, intended to support skin repair processes that decline with age. Each prescription requires review by a licensed provider, and the company reports 99.8% purity alongside microbial and endotoxin testing; compounded formulations are not FDA-approved. The launch places a well-characterized endogenous peptide into a clinician-supervised dosing model rather than an over-the-counter cosmetic one.
Key Points
- Prescription GHK-Cu cream offered at 0.5% and 3% concentrations
- Provider review required; compounded products lack FDA approval
- Purity reported at 99.8% with microbial and endotoxin testing
Longevity Analysis
GHK-Cu is an endogenous tripeptide whose circulating levels fall substantially from early adulthood onward, and its activity spans collagen remodeling, wound closure, capillary formation and antioxidant signaling — functions that sit at the intersection of tissue renewal, barrier defense and local blood supply. Topical repletion of a declining signaling molecule is a plausible strategy, but the clinically meaningful variables are concentration, treatment area and tolerance, which is why provider-directed titration matters more than the ingredient itself. Skin responds on the timescale of collagen turnover, so results depend on sustained daily application and periodic reassessment rather than short trials.
Original published by LT Wire.